OBJECTIVE: Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. METHOD OF STUDY: Eighty-one non-pregnant women were randomized into three groups and instructed to use Milex (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14 days in combination with one of the two acid-buffering microbicide gels [ACIDFORM (Instead Inc., La Jolla, CA, USA) or BufferGel(trade mark) (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K-Y Jelly); Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio-Plex or ELISA. RESULTS: Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. CONCLUSION: Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.
RCT Entities:
OBJECTIVE: Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. METHOD OF STUDY: Eighty-one non-pregnant women were randomized into three groups and instructed to use Milex (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14 days in combination with one of the two acid-buffering microbicide gels [ACIDFORM (Instead Inc., La Jolla, CA, USA) or BufferGel(trade mark) (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K-Y Jelly); Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio-Plex or ELISA. RESULTS: Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. CONCLUSION: Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.
Authors: B K Patterson; A Landay; J Andersson; C Brown; H Behbahani; D Jiyamapa; Z Burki; D Stanislawski; M A Czerniewski; P Garcia Journal: Am J Pathol Date: 1998-08 Impact factor: 4.307
Authors: Robert M Grant; Dean Hamer; Thomas Hope; Rowena Johnston; Joep Lange; Michael M Lederman; Judy Lieberman; Christopher J Miller; John P Moore; Donald E Mosier; Douglas D Richman; Robert T Schooley; Marty S Springer; Ronald S Veazey; Mark A Wainberg Journal: Science Date: 2008-07-25 Impact factor: 47.728
Authors: D'Nyce L Williams; Daniel R Newman; Susan A Ballagh; Mitchell D Creinin; Kurt Barnhart; Debra H Weiner; April J Bell; Denise J Jamieson Journal: Sex Transm Dis Date: 2007-12 Impact factor: 2.830
Authors: Kunihiko Doh; Parrin T Barton; Irina Korneeva; Sriram C Perni; Ann Marie Bongiovanni; Sara L Tuttle; Daniel W Skupski; Steven S Witkin Journal: Infect Dis Obstet Gynecol Date: 2004-06
Authors: Anna-Barbara Moscicki; Rupert Kaul; Yifei Ma; Mark E Scott; Ibrahim I Daud; Elizabeth A Bukusi; Stephen Shiboski; Anuradha Rebbapragada; Sanja Huibner; Craig R Cohen Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: H Irene Su; Courtney A Schreiber; Courtney Fay; Sam Parry; Michal A Elovitz; Jian Zhang; Alka Shaunik; Kurt Barnhart Journal: Contraception Date: 2011-03-29 Impact factor: 3.375
Authors: Joseph A Politch; Susan Cu-Uvin; Thomas R Moench; Karen T Tashima; Jai G Marathe; Kate M Guthrie; Howard Cabral; Tara Nyhuis; Miles Brennan; Larry Zeitlin; Hans M L Spiegel; Kenneth H Mayer; Kevin J Whaley; Deborah J Anderson Journal: PLoS Med Date: 2021-02-03 Impact factor: 11.613
Authors: Susan Tuddenham; Christina A Stennett; Richard A Cone; Jacques Ravel; Andrew N Macintyre; Khalil G Ghanem; Xin He; Rebecca M Brotman Journal: BMC Infect Dis Date: 2021-09-18 Impact factor: 3.090